Jun 18, 2019
Lannett Launches Aspirin And Extended-Release Dipyridamole Capsules
Jun 12, 2019
Arizona Care Network Partners with Solve.Care, Pharmaceutical Leader Boehringer Ingelheim To Launch Diabetes Care Administration Network
Mar 27, 2019
Lannett Receives FDA Approval For Aspirin And Extended-Release Dipyridamole Capsules, 25 mg/200 mg
Sep 27, 2018
UPMC Health Plan and Boehringer Ingelheim Announce Innovative, Value-Based Agreement
Jun 19, 2018
Medisafe Announces Partnership with Boehringer Ingelheim to Support U.S. Pradaxa Patients
Mar 09, 2018
Boehringer Ingelheim to Present New Research on Pradaxa and Specific Reversal Agent Praxbind at American College of Cardiology Scientific Session
Mar 06, 2018
Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials
Feb 16, 2018
New initiative raises awareness of scleroderma through real-life stories of those living with the rare disease
Feb 09, 2018
Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer's trials
Jan 25, 2018
New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment
Jan 16, 2018
FDA approves new indication for Gilotrif® in EGFR mutation-positive NSCLC
Jan 10, 2018
Boehringer Ingelheim's Respimat Inhaler Awarded Arthritis Foundation's Ease of Use Commendation
Dec 20, 2017
Knowledge Of Biosimilars: Survey Of 100+ U.S. Rheumatologists Shows Familiarity But Need For Further Education
Dec 12, 2017
Boehringer Ingelheim initiates real-world study of treatment sequencing in EGFR mutation-positive lung cancer
Dec 07, 2017
Holiday Program Brings Hope Home to Lung Cancer Patients
Nov 13, 2017
New RE-VERSE AD(TM) Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery
Nov 10, 2017
Boehringer Ingelheim Presents New Data for Pradaxa® and its Specific Reversal Agent Idarucizumab (Praxbind®) at AHA Scientific Sessions 2017
Nov 10, 2017
Results from six-month lung imaging study showed slowing of fibrotic progression in patients with IPF treated with Ofev® versus placebo
Oct 30, 2017
Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy
Oct 23, 2017
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function